Syneos Health has expanded its Decentralized Clinical Trial capabilities to include a dedicated Decentralized Clinical Trials Site Advocacy Group. The Group will engage with sites and community stakeholders including patients, advocacy groups, industry, academic centers and sponsors, securing valuable insights across the clinical to commercial spectrum—from the mobile research nursing solutions provided by Illingworth Research Group—aiming to better inform decentralized protocol design, data capture and patient retention strategies. The Group will pressure-test, problem-solve and co-create innovative decentralized clinical trial methodologies.
This collaboration expands the existing Syneos Health Scientific and Protocol Optimization Site Advocacy Group program, introduced in 2015.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.